These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21648175)

  • 41. Rightsizing cervical cancer screening: comment on "Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone".
    Sawaya GF
    Arch Intern Med; 2010 Jun; 170(11):985-6. PubMed ID: 20548012
    [No Abstract]   [Full Text] [Related]  

  • 42. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
    Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
    Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.
    Dunne EF; Datta SD; E Markowitz L
    Cancer; 2008 Nov; 113(10 Suppl):2995-3003. PubMed ID: 18980283
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine in a sexually active population of North American women.
    Barr E; Gause CK; Bautista OM; Railkar RA; Lupinacci LC; Insinga RP; Sings HL; Haupt RM
    Am J Obstet Gynecol; 2008 Mar; 198(3):261.e1-11. PubMed ID: 18313445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
    Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
    Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of cervical cancer.
    Denny L
    Reprod Health Matters; 2008 Nov; 16(32):18-31. PubMed ID: 19027619
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gardasil needs a new consent form.
    Harper DM
    Expert Rev Vaccines; 2009 Dec; 8(12):1613-4. PubMed ID: 19943754
    [No Abstract]   [Full Text] [Related]  

  • 49. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
    Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
    Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The human papillomavirus vaccine and its relevance in Israel.
    Menczer J
    Isr Med Assoc J; 2007 Jul; 9(7):546-9. PubMed ID: 17710788
    [No Abstract]   [Full Text] [Related]  

  • 51. [Vaccination perspective against human papillomavirus and consequences for the screening of uterine cervical neoplasm].
    Delvenne P
    Bull Mem Acad R Med Belg; 2007; 162(10-12):483-8; discussion 489-90. PubMed ID: 18557390
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France.
    Bergeron C; Largeron N; McAllister R; Mathevet P; Remy V
    Int J Technol Assess Health Care; 2008; 24(1):10-9. PubMed ID: 18218164
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
    Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
    Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer Screening and Prevention Highlights in Gynecologic Cancer.
    Staples JN; Duska LR
    Obstet Gynecol Clin North Am; 2019 Mar; 46(1):19-36. PubMed ID: 30683264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Influential groups propose less frequent cervical cancer screening for most women.
    Kuehn BM
    JAMA; 2011 Dec; 306(21):2311-2. PubMed ID: 22147373
    [No Abstract]   [Full Text] [Related]  

  • 56. [Gynecological screening or cervical screening? Conflicts between clinical and public health viewpoints].
    Döbrőssy L; Kovács A; Budai A; Cornides A
    Orv Hetil; 2012 Aug; 153(33):1302-13. PubMed ID: 22890177
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Human papillomavirus vaccine: optimism versus prudence].
    Martínez-González MA; Carlos S; de Irala J
    Med Clin (Barc); 2008 Sep; 131(7):256-63. PubMed ID: 18775217
    [No Abstract]   [Full Text] [Related]  

  • 58. [Vaccination against HPV-associated neoplasias].
    Gross G; Becker N; Brockmeyer NH; Esser S; Freitag U; Gebhardt M; Gissmann L; Hillemanns P; Grundhewer H; Ikenberg H; Jessen H; Kaufmann A; Klug S; Klussmann JP; Nast A; Pathirana D; Petry KU; Pfister H; Röllinghof U; Schneede P; Schneider A; Selka E; Singer S; Smola S; Sporbeck B; von Knebel Doeberitz M; Wutzler P;
    Laryngorhinootologie; 2014 Dec; 93(12):848-56. PubMed ID: 25437625
    [No Abstract]   [Full Text] [Related]  

  • 59. Molecular testing of gynecologic cytology specimens: Beyond HPV.
    Gibson JS
    Cancer Cytopathol; 2016 Oct; 124(10):687-688. PubMed ID: 27599379
    [No Abstract]   [Full Text] [Related]  

  • 60. Vaccine against human papilloma virus.
    Reina JC; Muñoz N
    Colomb Med (Cali); 2014; 45(3):94-5. PubMed ID: 25386033
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.